CA1176173A - Process for obtaining a drug useful in the treatment of arthritis and other diseases of the locomotive system - Google Patents
Process for obtaining a drug useful in the treatment of arthritis and other diseases of the locomotive systemInfo
- Publication number
- CA1176173A CA1176173A CA000374387A CA374387A CA1176173A CA 1176173 A CA1176173 A CA 1176173A CA 000374387 A CA000374387 A CA 000374387A CA 374387 A CA374387 A CA 374387A CA 1176173 A CA1176173 A CA 1176173A
- Authority
- CA
- Canada
- Prior art keywords
- extract
- rhyzomes
- polar solvent
- polar
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 18
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 13
- 206010003246 arthritis Diseases 0.000 title claims description 11
- 230000008569 process Effects 0.000 title claims description 11
- 230000003137 locomotive effect Effects 0.000 title claims 3
- 241000985694 Polypodiopsida Species 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000012454 non-polar solvent Substances 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 239000003957 anion exchange resin Substances 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 241000196124 Polypodiaceae Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 241000208365 Celastraceae Species 0.000 claims description 2
- 241001518160 Pleopeltis Species 0.000 claims description 2
- 235000000336 Solanum dulcamara Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 241001362938 Microgramma Species 0.000 claims 1
- 241001624848 Phlebodium Species 0.000 claims 1
- 241001518143 Polypodium <fern> Species 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical group [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000000727 fraction Substances 0.000 claims 1
- 239000011343 solid material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001575 pathological effect Effects 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002456 anti-arthritic effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 101150034533 ATIC gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001061225 Arcos Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001362811 Niphidium Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000428533 Rhis Species 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000059 bradycardiac effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES490.293 | 1980-04-02 | ||
| ES490293A ES8104315A1 (es) | 1980-04-02 | 1980-04-02 | Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1176173A true CA1176173A (en) | 1984-10-16 |
Family
ID=8480183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000374387A Expired CA1176173A (en) | 1980-04-02 | 1981-04-01 | Process for obtaining a drug useful in the treatment of arthritis and other diseases of the locomotive system |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR224063A1 (enrdf_load_stackoverflow) |
| AU (1) | AU538973B2 (enrdf_load_stackoverflow) |
| CA (1) | CA1176173A (enrdf_load_stackoverflow) |
| DE (1) | DE3111056A1 (enrdf_load_stackoverflow) |
| ES (1) | ES8104315A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2479690A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2075834A (enrdf_load_stackoverflow) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0503208A1 (en) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns |
| ES2088770B1 (es) * | 1995-02-23 | 1997-03-16 | Esp Farmaceuticas Centrum Sa | Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. |
| US5614197A (en) * | 1995-02-13 | 1997-03-25 | Industrial Farmaceutica Cantabria, S.A. | Polypodium extract as photoprotectant |
| ES2137900B1 (es) * | 1998-06-02 | 2000-08-16 | Helsint S A L | Empleo de formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum como complemento nutricional en el tratamiento del sindrome caquectico en pacientes oncologicos. |
| ES2124675B1 (es) * | 1997-07-30 | 1999-10-01 | Helsint S A L | "formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum, y su uso en el tratamiento del sindrome caquectico en enfermos de sida". |
| WO1999006058A1 (es) * | 1997-07-30 | 1999-02-11 | Helsint, S.A.L. | Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer |
| US6228366B1 (en) * | 1998-07-29 | 2001-05-08 | Helsint, S.A.L. | Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients |
| ES2146555B1 (es) * | 1999-01-22 | 2001-03-01 | Helsint S A L | Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y/o polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobresfuerzo fisico. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB256768A (en) * | 1925-07-17 | 1926-08-19 | Francesco Fumarola | Process for extraction of the active biological principles from the ether extract of male fern |
| US3395223A (en) * | 1965-05-13 | 1968-07-30 | Carter Wallace | Fern extract for treating gastric ulcers |
| ES470204A1 (es) * | 1978-05-24 | 1979-01-01 | Conrad Ltd | Procedimiento de obtencion de terpenos naturales con activi-dad antipsoriatica |
| ES471572A1 (es) * | 1978-07-07 | 1979-01-16 | Conrad Ltd | Procedimiento de obtencion de fraccion polar natural con ac-tividad antipsoriatica |
-
1980
- 1980-04-02 ES ES490293A patent/ES8104315A1/es not_active Expired
-
1981
- 1981-03-20 DE DE3111056A patent/DE3111056A1/de not_active Withdrawn
- 1981-03-25 AR AR284728A patent/AR224063A1/es active
- 1981-03-26 GB GB8109495A patent/GB2075834A/en not_active Withdrawn
- 1981-03-31 AU AU68934/81A patent/AU538973B2/en not_active Expired - Fee Related
- 1981-04-01 FR FR8106562A patent/FR2479690A1/fr active Granted
- 1981-04-01 CA CA000374387A patent/CA1176173A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AR224063A1 (es) | 1981-10-15 |
| DE3111056A1 (de) | 1982-02-11 |
| FR2479690B1 (enrdf_load_stackoverflow) | 1984-11-02 |
| ES490293A0 (es) | 1981-04-16 |
| AU538973B2 (en) | 1984-09-06 |
| AU6893481A (en) | 1981-10-08 |
| FR2479690A1 (fr) | 1981-10-09 |
| ES8104315A1 (es) | 1981-04-16 |
| GB2075834A (en) | 1981-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4511559A (en) | Biologically active polysaccharide concentrates and process for production of preparates containing such substances | |
| DE69431024T2 (de) | Neues physiologisch aktives Mittel | |
| CN101129475B (zh) | 一种葎草属植物的提取物、其用途和含有该提取物的药物组合物 | |
| CA1176173A (en) | Process for obtaining a drug useful in the treatment of arthritis and other diseases of the locomotive system | |
| CA1106285A (en) | Process for obtaining a natural polar fraction having anti-psoriatic activity | |
| CN101780070B (zh) | 一种治疗糖尿病肾病的药物组合物及其制备方法 | |
| CN109966449A (zh) | 一种治疗眩晕病的中药制剂的制备方法及其制备的制剂 | |
| DE68926025T2 (de) | Methode zur Herstellung von alpha-Amylase hemmenden Substanzen aus Weizen | |
| CN101461928B (zh) | 一种半夏厚朴汤制剂的制备方法 | |
| CN101007071A (zh) | 治疗急、慢性肠、胃炎及细菌性痢疾的中药及其制备工艺 | |
| CN1240407C (zh) | 具有α一糖苷酶抑制剂活性的中药提取物、其制备方法及用途 | |
| EP0503208A1 (en) | Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns | |
| KR100601390B1 (ko) | 혼합 생약재를 이용한 비만 억제용 조성물 | |
| CH663153A5 (de) | Arzneimittel in form eines tannin-gemisches und seine herstellung. | |
| CN1723981A (zh) | 罗汉果提取物用于制备药物辅料的新用途 | |
| CN101129972B (zh) | 一种中药组合物、其制备方法及其用途 | |
| JPH0475890B2 (enrdf_load_stackoverflow) | ||
| CA1122589A (en) | Process for obtaining natural terpenes having an antipsoriatic activity | |
| CN102499322B (zh) | 具有促进记忆改善的保健类食品或药品 | |
| KR101775071B1 (ko) | 호박손 추출물을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 약학적 조성물 | |
| CN101804128B (zh) | 一种治疗炎症性肠病的药物组合物及该组合物在制备治疗炎症性肠病药物中的用途 | |
| JPH02157297A (ja) | 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤 | |
| CN101455773B (zh) | 金刚藤分散片及其制备方法 | |
| CN106389594A (zh) | 一种治疗夜盲症的中药组合物及其制备方法 | |
| JPS6183130A (ja) | 多糖類，その単離法および用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |